CN102559528A - 一种产甜叶菊糖基转移酶ugt76g1的基因工程菌及其应用 - Google Patents
一种产甜叶菊糖基转移酶ugt76g1的基因工程菌及其应用 Download PDFInfo
- Publication number
- CN102559528A CN102559528A CN2012100291582A CN201210029158A CN102559528A CN 102559528 A CN102559528 A CN 102559528A CN 2012100291582 A CN2012100291582 A CN 2012100291582A CN 201210029158 A CN201210029158 A CN 201210029158A CN 102559528 A CN102559528 A CN 102559528A
- Authority
- CN
- China
- Prior art keywords
- rebaudioside
- ugt
- consumption
- glucose
- stevioside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 41
- 101100262416 Stevia rebaudiana UGT76G1 gene Proteins 0.000 title claims abstract 7
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 title abstract description 55
- 108700023372 Glycosyltransferases Proteins 0.000 title abstract description 8
- 102000051366 Glycosyltransferases Human genes 0.000 title abstract description 7
- 244000228451 Stevia rebaudiana Species 0.000 title abstract description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 29
- 239000008103 glucose Substances 0.000 claims abstract description 29
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 15
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 15
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims abstract description 15
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 15
- 239000000758 substrate Substances 0.000 claims abstract description 15
- 239000013612 plasmid Substances 0.000 claims abstract description 13
- GIPHUOWOTCAJSR-UHFFFAOYSA-N Rebaudioside A. Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC1OC(CO)C(O)C(O)C1OC(C1O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O GIPHUOWOTCAJSR-UHFFFAOYSA-N 0.000 claims abstract description 9
- 230000001105 regulatory effect Effects 0.000 claims abstract description 5
- 108091008146 restriction endonucleases Proteins 0.000 claims abstract description 5
- 238000010276 construction Methods 0.000 claims abstract description 4
- 235000019202 steviosides Nutrition 0.000 claims description 48
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 46
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 46
- 229940013618 stevioside Drugs 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 35
- 238000006243 chemical reaction Methods 0.000 claims description 23
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 22
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 21
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 238000010353 genetic engineering Methods 0.000 claims description 17
- 239000008057 potassium phosphate buffer Substances 0.000 claims description 15
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 14
- 229930182817 methionine Natural products 0.000 claims description 14
- 229960005010 orotic acid Drugs 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 8
- 239000001384 succinic acid Substances 0.000 claims description 8
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 7
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 7
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 7
- 239000004473 Threonine Substances 0.000 claims description 7
- 229960005261 aspartic acid Drugs 0.000 claims description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- 229960005190 phenylalanine Drugs 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 229960004799 tryptophan Drugs 0.000 claims description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 7
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- 102000004357 Transferases Human genes 0.000 claims description 4
- 108090000992 Transferases Proteins 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 230000003197 catalytic effect Effects 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 230000029087 digestion Effects 0.000 claims description 4
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 4
- 239000002207 metabolite Substances 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- 238000005215 recombination Methods 0.000 claims description 4
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 239000002054 inoculum Substances 0.000 claims description 3
- 239000012264 purified product Substances 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 230000008676 import Effects 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- 239000001512 FEMA 4601 Substances 0.000 abstract description 46
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 abstract description 46
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 abstract description 46
- 235000019203 rebaudioside A Nutrition 0.000 abstract description 46
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-alpha-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 abstract description 13
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 abstract description 13
- 238000006555 catalytic reaction Methods 0.000 abstract description 13
- 229930182470 glycoside Natural products 0.000 abstract description 6
- 150000002338 glycosides Chemical class 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000037353 metabolic pathway Effects 0.000 abstract description 2
- 102000016354 Glucuronosyltransferase Human genes 0.000 abstract 2
- 108010092364 Glucuronosyltransferase Proteins 0.000 abstract 2
- 229930182478 glucoside Natural products 0.000 description 17
- 101710171974 UDP-glycosyltransferase 76G1 Proteins 0.000 description 16
- 241000544066 Stevia Species 0.000 description 15
- -1 Rebaudioside A glucoside Chemical class 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 229930006000 Sucrose Natural products 0.000 description 11
- 239000005720 sucrose Substances 0.000 description 11
- 239000007791 liquid phase Substances 0.000 description 10
- 230000000149 penetrating effect Effects 0.000 description 10
- 239000013049 sediment Substances 0.000 description 10
- 239000013595 supernatant sample Substances 0.000 description 10
- 230000004060 metabolic process Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- QFVOYBUQQBFCRH-UHFFFAOYSA-N Steviol Natural products C1CC2(C3)CC(=C)C3(O)CCC2C2(C)C1C(C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-UHFFFAOYSA-N 0.000 description 5
- 150000008131 glucosides Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- QFVOYBUQQBFCRH-VQSWZGCSSA-N steviol Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)CC1)C[C@H]2[C@@]2(C)[C@H]1[C@](C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-VQSWZGCSSA-N 0.000 description 5
- 229940032084 steviol Drugs 0.000 description 5
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229930188195 rebaudioside Natural products 0.000 description 4
- QSRAJVGDWKFOGU-WBXIDTKBSA-N rebaudioside c Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]1(CC[C@H]2[C@@]3(C)[C@@H]([C@](CCC3)(C)C(=O)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)CC3)C(=C)C[C@]23C1 QSRAJVGDWKFOGU-WBXIDTKBSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000235648 Pichia Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000021096 natural sweeteners Nutrition 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- OMHUCGDTACNQEX-OSHKXICASA-N steviolbioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OMHUCGDTACNQEX-OSHKXICASA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000001776 FEMA 4720 Substances 0.000 description 2
- 101100427140 Stevia rebaudiana UGT74G1 gene Proteins 0.000 description 2
- 101100048059 Stevia rebaudiana UGT85C2 gene Proteins 0.000 description 2
- HSCJRCZFDFQWRP-RDKQLNKOSA-N UDP-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-RDKQLNKOSA-N 0.000 description 2
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- QSIDJGUAAUSPMG-CULFPKEHSA-N steviolmonoside Chemical compound O([C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QSIDJGUAAUSPMG-CULFPKEHSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000189115 Catananche Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N Rohrzucker Natural products OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- 239000004383 Steviol glycoside Substances 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 description 1
- DQQDLYVHOTZLOR-OCIMBMBZSA-N UDP-alpha-D-xylose Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)OP(O)(=O)OP(O)(=O)O[C@H]1OC[C@@H](O)[C@H](O)[C@H]1O DQQDLYVHOTZLOR-OCIMBMBZSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- ZTYNVDHJNRIRLL-FWZKYCSMSA-N rhodostomin Chemical compound C([C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CSSC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(O)=O)[C@@H](C)O)=O)CSSC[C@H]2C(=O)N[C@H]3CSSC[C@@H](C(NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H]2NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)CN)CSSC2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N4)=O)CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N[C@@H](CCCCN)C(=O)N1)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=CC=C1 ZTYNVDHJNRIRLL-FWZKYCSMSA-N 0.000 description 1
- 108010049985 rhodostomin Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000006250 specific catalysis Methods 0.000 description 1
- 229930182488 steviol glycoside Natural products 0.000 description 1
- 235000019411 steviol glycoside Nutrition 0.000 description 1
- 150000008144 steviol glycosides Chemical class 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明公开了一种产甜叶菊糖基转移酶UGT76G1的基因工程菌,它是将UGT76G1编码基因插入PYes2载体的EcoRI和XhoI酶切位点之间,构建了重组质粒,再将重组质粒导入表达宿主酿酒酵母Saccharomyces cerevisiaeYPH499中得到的工程菌;其中,所述的UGT76G1编码基因为GenBank,No.GenBank:AY345974.1,该基因序列命名为UGT。本发明还公开了上述基因工程菌的构建方法及在生产莱鲍迪甙A中的应用。本发明在不外加昂贵UDPG的情况下,以廉价碳源葡萄糖为底物,调节酵母体内UDPG的代谢途径,全细胞催化St甙生成rebaudioside A。
Description
技术领域
本发明涉及一种产甜叶菊糖基转移酶UGT76G1的基因工程菌及其应用,属于生物工程技术领域。
背景技术
甜味剂是食品工业中最广泛的添加剂,按其来源分为天然甜味剂和人工合成甜味剂。在天然甜味剂中,应用最多的是蔗糖,但蔗糖是一种高热量的甜味剂,摄入过多会导致人体肥胖、糖尿病、龋齿等疾病的发牛[1,2,3,4]。人工合成的甜味剂,如甜精(dulin,对-乙氧基苯脲)、环己氨基磺酸盐(cyclamata),虽然可以使人们对甜味得到满足,但相继被发现有毒副作用而被禁用;糖精(saccharin,邻磺酰苯甲酰亚胺),也因被报道有致癌作用而可能被限制使用。寻找无毒、安全、低热能、高甜度的天然甜味剂一直是科学研究的热点。
甜叶菊(Stevia rebaudiana bertoni),又名甜菊、糖草,是原产于南美巴拉圭等地的一种野生菊科草本植物,它是目前已知甜度较高的糖料植物之一[5]。甜菊糖(Steviolglycosides)是从甜叶菊的叶、茎中提取出的一种新型天然甜味剂。它具有高甜度、低热能的特点,其甜度是蔗糖的150~300倍,热值仅为蔗糖的1/300[6]。经大量药物实验证明,甜菊糖无毒副作用,无致癌物,食用安全,经常食用可预防高血压、糖尿病、肥胖症、心脏病、龋齿等病症[7,8,9],是一种可替代蔗糖非常理想的甜味剂。甜菊糖可广泛应用于食品、饮料、医药、日用化工、酿酒、化妆品等行业[11],并且较应用蔗糖可节省成本60%。甜菊糖是目前世界已发现并经我国卫生部、轻工业部批准使用的最接近蔗糖口味的天然低热值甜味剂[10]。是继苷蔗、甜菜糖之外第三种有开发价值和健康推崇的天然蔗糖替代品,被国际上誉为“世界第三糖源”。
甜菊叶中三种最主要的糖甙成分在叶片中的含量通常为:甜菊甙(stevioside,stevioside)占叶片干重9.1%,莱鲍迪甙A(rebaudioside A,rebaudioside A甙)占3.8%,莱鲍迪甙C(rebaudioside C,RC甙)占0.6%[12]。市售甜菊糖一般以stevioside为主要成分,该组分甜度为蔗糖的200倍左右,其后味略带甘苦味。而作为甜菊糖的第二主成分,rebaudioside A甙甜度为蔗糖400倍,口味纯正,没有后苦味。因此,提高rebaudioside A甙相对含量是提高甜菊糖品质的关键步骤。
目前文献报道提高rebaudioside A甙相对含量的策略有:(1)培育rebaudioside A甙高含量的甜菊品种,国内已经尝试成功通过嫁接方法,获得rebaudioside A甙含量超过40%品种,但该品种不具备普适性,且品种容易退化,不适宜大面积种植[11];(2)通过纯化提高rebaudioside A甙与stevioside的比例,此法由于天然植物中rebaudioside A甙含量低于stevioside,且二者物理性质极为相近,使得纯化工艺难度很大,得率较低。这两种方法的高成本造成目前市场上高rebaudioside A甙含量的甜菊糖价格很高,含80%rebaudioside A甙的甜菊糖市价比一般混合型甜菊糖要高出4~5倍。另有报道,可以利用环糊精糖基转移酶修饰法改进甜菊糖的口感和味质,但是该法严重降低甜度,因此也不是最佳的解决方案。总之,目前已有的方法都不适宜推广。因此,寻求高效的生物酶法转化途径已经成为提高rebaudioside A甙相对含量的必然趋势。
糖基转移酶UGT76G1作为植物糖基转移酶家族的一员,可以特异性的催化甜叶菊中的stevioside,生成rebaudioside A甙,因此有着重要的研究价值。Richman等从甜叶菊的EST中分离了3种UGTs基因[13],UGT85C2、UGT74G1、UGT76G1。体外活性分析表明,UGT85C2催化甜菊醇到甜菊单甙(steviolmonoside)的反应,UGT74G1主要催化甜菊双甙(steviolbioside)的糖基化反应,产生stevioside。而stevioside到rebaudiosideA甙由UGT76G1一步糖基化反应完成,见图1。Humphrey等人的实验结果也证实了此过程[14]。
UGT76G1全称为UDP-glycosyltrebaudioside Ansferebaudioside Ase 76G1,其编码基因(Genbank code:AY345974)全长1616bp,开放读码框长度为1374bp,编码458个氨基酸。有关UGT76G1的相关研究报道非常少,UDP-糖基转移酶76G1(UGT76G1)作为糖基转移酶家族的一员,可以选择性催化stevioside生成rebaudioside A甙,在甜菊糖生产方面具有潜在的应用价值。本专利首要目的是采用基因工程手段,将UGT76G1在Saccharomyces cerevisiae中实现表达,并该酶的催化特性进行研究。
其次,考虑到Saccharomyces cerevisiae表达系统与其他表达系统相比,其适度的糖基化修饰过程更适合植物蛋白的表达[15-18];此外UGT76G1在催化反应时需要加入UDPG作为糖供体,而Saccharomyces cerevisiae系统可能会比大肠杆菌系统提供更多的天然糖供体而减少催化成本。基于以上考虑,将UGT76G1在Saccharomyces cerevisiae系统中实现表达,可以为利用重组菌进行全细胞催化stevioside生成rebaudioside A甙的工艺奠定基础。
UDPG是一种重要的核苷二磷酸单糖,1950年由Leloir和他的同事在研究半乳糖向葡萄糖转化过程中首次发现[19]。UDPG是高等植物中活化糖的主要形式,作为葡萄糖基供体参与蔗糖、纤维素、半纤维素、果胶质以及糖脂、糖蛋白的合成代谢。UDPG还是合成其他核苷二磷酸单糖,如尿苷二磷酸半乳糖、尿苷二磷酸葡萄糖酸、尿苷二磷酸木糖等的前体。尿苷二磷酸葡萄糖的生物合成过程如图2所示。
参考文献
[1]舒进珍等,中国甜菊栽培及应用技术[M],北京:中国农业出版社,1989年,98~107.
[2]徐任生主编,天然产物化学[M],北京:科学出版社,2004年,351~377.
[3]Lombardo YB,Drebaudioside Ago S,Chicco A,et al.Long-term administrebaudiosideAtion of a sucrose-rich diet to normal rebaudioside Ats:relationship between metabolic andhormonal profiles and morphological changes in the endocrine pancreas[J].Metabolism,1996,245:1527~1532.
[4]Ten S,and Maclaren N.Insulin resistance syndrome in children[J].Clin Endocrinol Metab,2004,89:2526~2539.
[5]Kovylyaeva GI,Bakaleinik GA,Strobykina IYu,et al.Glycosides from Steviarebaudiana[J].Chemistry of Naturebaudioside Al Compounds,2007,43(1):81~85.
[6]陈慕英,于喜水孙玉华,等.中医药信息[J].2001,18(3):23.
[7]JanM C·Geuns·Phytochemistry[M],2003,64:913·
[8]Carebaudioside Akostas MC,Curry LL,Boileau AC,et al.Overview:the history,technicalfunction and safety of rebaudioside A,a naturebaudioside Ally occurring steviol glycoside,foruse in food and beverebaudioside Ages[J].Food Chem Toxicol,2008,46 Suppl 7:S1~S10.
[9]Shibata H,et al.Glucosylation of steviol and steviol-glucosides in extrebaudioside Actsfrom Stevia rebaudiana Bertoni[J].Plant Physiol,1991,95(1):152~156.
[10]Shibata H,et al.Steviol and steviol-glycosideglucosyltrebaudioside AnsferebaudiosideAse activities in Stevia rebaudiana Bertoni-purification and partial charebaudiosideActerization[J].Arch Biochem Biophys,1995,321(2):390~396.
[11]Humphrey TV,Richman AS,Menassa R,et al.Spatial organisation of four enzymes fromStevia rebaudiana that are involved in steviol glycoside[J].Plant Mol.Biol,2006,61:47~62
[12]Brebaudioside Andle JE,et al.Steviol glycoside biosynthesis[J].Phytoehemistry,2007,68(14):1855~1863.
[13]黄应森.中国甜菊和甜菊糖甙的分型研究[J].中国糖料,1999,4:26~29..
[14]Chatsudthipong V,and Muanprebaudioside Asat C.Stevioside and related compounds:therebaudioside Apeutic benefits beyond sweetness.Pharmacol Ther,2009,121:41~54.
[15]Hilario E,Lataro RC,Alegria MC,et al.High level production of functional muscle alphatropomyosin in Pichia pastoris[J].Biochem Biophys Res Commun,2001,284(4):955~60.
[16]Zani M,Brillard Bourdet M,Lazure C,et al.Purification and charebaudiosideActerization of active recombinant rebaudioside At kallikrein rK9[J].Biochim Biophys Acta,2001,1547(2):387~396.
[17]Guo RT,Chou LJ,Chen YC,et al.Expression in Pichia pastoris and charebaudiosideActerization by circular dichroism and NMR of rhodostomin[J].Proteins,2001,43(4):499~508.
[18]Rydberg EH,Sidhu G,Vo HC,et al.Cloning,mutagenesis,and structurebaudioside Alanalysis of human pancreatic alpha amylase expressed in Pichia pastoris[J].Protein Sci,1999,8(3):635~643.
[19]Caputto R,Leloir LF,Cardini CE,et al.Isolation of the coenzyme of the galactosephosphate-glucosephosphate trebaudioside Ansformation.J Bio Chem,1950,184:333-350
发明内容
本发明所要解决的第一个技术问题是提供一株能够表达糖基转移酶UGT76G1的工程菌。
本发明所要解决的第二个技术问题是提供上述工程菌的构建方法。
本发明所要解决的第三个技术问题是提供上述工程菌的诱导表达方法。
本发明所要解决的第四个技术问题是提供上述工程菌的应用。
一种产甜叶菊糖基转移酶UGT76G1的基因工程菌,它是将UGT76G1编码基因插入PYes2载体的EcoRI和XhoI酶切位点之间,构建了重组质粒,再将重组质粒导入表达宿主酿酒酵母Saccharomyces cerevisiaeYPH499中得到的工程菌;
其中,所述的UGT76G1编码基因为GenBank,No.GenBank:AY345974.1,该基因序列命名为UGT。
上述基因工程菌的构建方法,该方法包括如下步骤:
1)用限制性内切酶EcoR I和Sal I双酶切UGT基因片段和PYes2载体,连接UGT基因片段纯化产物与PYes2载体,得到重组质粒PYes2-UGT;
2)将重组质粒PYes2-UGT转化至DH5α感受态细胞,得到重组大肠杆菌DH5α-PYes2-UGT,选取阳性克隆;
3)将鉴定后的阳性克隆的质粒导入酿酒酵母Saccharomyces cerevisiaeYPH499中,得到基因工程菌YPH499-PYes2-UGT。
上述基因工程菌的诱导表达方法,以半乳糖为诱导剂诱导基因工程菌产酶。
上述基因工程菌的诱导表达方法,具体来说,将基因工程菌按2~5(v/v)%接种量接种到碳源为20g/L葡萄糖的培养基上,培养8~16h,然后收集菌体,将菌体转移到碳源为20g/L半乳糖的培养基中诱导,诱导时间为48~60h;所述的碳源为20g/L葡萄糖的培养基配方为:6.7g/L YNB,20g/L葡萄糖,0.1g/L腺嘌呤,0.1g/L精氨酸,0.1g/L半胱氨酸,0.1g/L亮氨酸,0.1g/L赖氨酸,0.1g/L苏氨酸,0.1g/L色氨酸,0.05g/L天冬氨酸,0.05g/L组氨酸,0.05g/L异亮氨酸,0.05g/L甲硫氨酸,0.05g/L苯丙氨酸,0.05g/L脯氨酸,0.05g/L丝氨酸,0.05g/L酪氨酸,0.05g/L缬氨酸;所述的碳源为20g/L半乳糖的培养基配方为:6.7g/L YNB,20g/L半乳糖,0.1g/L腺嘌呤,0.1g/L精氨酸,0.1g/L半胱氨酸,0.1g/L亮氨酸,0.1g/L赖氨酸,0.1g/L苏氨酸,0.1g/L色氨酸,0.05g/L天冬氨酸,0.05g/L组氨酸,0.05g/L异亮氨酸,0.05g/L甲硫氨酸,0.05g/L苯丙氨酸,0.05g/L脯氨酸,0.05g/L丝氨酸,0.05g/L酪氨酸,0.05g/L缬氨酸。
上述基因工程菌在生产莱鲍迪甙A中的应用。即利用全细胞催化法,将甜菊甙转化为莱鲍迪甙A。具体来说,是以诱导表达后的基因工程菌为全细胞催化剂,通过加入表面活性剂改变细胞的通透性,以甜菊甙和葡萄糖为底物,添加镁离子以及调节代谢物质,反应得到莱鲍迪甙A。
基因工程菌的用量按湿菌体计为2g/L;甜菊甙的用量为1g/L;葡萄糖的用量为20g/L;所述的表面活性剂为普郎尼克F-68,用量为1~10g/L,优选2g/L;镁离子使用MgCl2,用量为1~10g/L,优选6g/L。
所述的调节代谢物质分别有UMP、丁二酸、乳清酸或柠檬酸,UMP用量为0.5~3g/L,优选1.5g/L;丁二酸用量为5~10g/L,优选9g/L;乳清酸用量为为1~5g/L,优选2g/L;柠檬酸用量为10~20g/L,优选15g/L。
所述的反应在磷酸钾缓冲液体系中完成,反应pH6.8~7.8,优选7.2,反应温度25~42℃,优选37℃,反应时间12~96h,优选72h。
有益效果:本发明在不外加昂贵UDPG的情况下,以廉价碳源葡萄糖为底物,调节酵母体内UDPG的代谢途径,全细胞催化St甙生成rebaudioside A。其中,添加UMP,最高达到115mg/L;添加丁二酸,最高达到180mg/L;添加乳清酸,最高达到270mg/L;添加柠檬酸,rebaudioside A产量最高达到675mg/L;说明添加柠檬酸等物质能够有效促进酵母体内UDPG的合成。另外,在添加柠檬酸的前提下,研究催化反应体系的PH值、反应温度以及时间,最终获得最佳反应调节为PH7.2、反应温度37℃、反应时间72h,此条件下rebaudioside A产量高达875mg/L。
附图说明
图1糖基转移酶催化甜菊醇生成rebaudioside A甙的途径。
图2酵母体内的UDP-葡萄糖合成代谢途径。
具体实施方式
根据下述实施例,可以更好地理解本发明。然而,本领域的技术人员容易理解,实施例所描述的内容仅用于说明本发明,而不应当也不会限制权利要求书中所详细描述的本发明。
实施例1:重组酵母菌的构建。
1、糖基转移酶UGT基因的获取:
根据AY345974.1基因序列,进行密码子优化,优化后的基因序列命名为UGT由南京金思瑞公司完成基因合成。
根据UGT基因序列设计引物
上游引物(-sense含EcoRI)为:
5′-CGGAATTCAAACAATGTCTGAAAATAAGACTGAAACTACTG-3′
下游游引物(-sense含XhoI)为:
5′-CCGCTCGAGTTATAATGATGAAATATAAGAAACCAA-3′
所有引物由上海申能博彩公司合成。
基因的PCR条件(50μL体系):
94℃变性5min;
按如下参数循环30次:94℃变性30S,60℃退火30s,72℃延伸2min;
最后72℃延伸10min。
2、重组工程菌YPH499-PYes2-UGT获得:
以合成的带有UGT基因的质粒为模板,用引物进行PCR扩增。将UGT基因片段纯化产物和PMD18-T Vector载体双酶切胶回收产物,用T4连接酶16℃进行UGT片段纯化产物与PMD18-T Vector的连接,将10ul的连接物产物PMD18-T-UGT热击转化至DH5α感受态中。转化物涂布于含有含100ug/mlAp的平板上,37℃培养过夜,筛选阳性克隆。获得正确序列的克隆载体PMD18-T-UGT。
分别用EcoRI和XhoI双酶切克隆载体PMD18-T-UGT和PYes2。胶回收酶切产物后进行连接反应,构建出表达载体PYes2-UGT。将鉴定后正确的阳性克隆载体PYes2-UGT与Saccharomyces cerevisiae YPH499感受态混匀,电击法转化完毕后,加入1mL冰预冷的山梨醇溶液将菌体混匀,将菌体悬液涂布于SC-U筛选培养基平板上至于30℃培养,直至单个菌落出现。
液体培养基的配方如下:
完全培养基YPD:10g/L酵母提取物,20g/L蛋白胨,20g/L葡萄糖。
选择培养基SC-U:6.7g/L YNB,20g/L碳源(葡萄糖),0.1g/L腺嘌呤,0.1g/L精氨酸,0.1g/L半胱氨酸,0.1g/L亮氨酸,0.1g/L赖氨酸,0.1g/L苏氨酸,0.1g/L色氨酸,0.05g/L天冬氨酸,0.05g/L组氨酸,0.05g/L异亮氨酸,0.05g/L甲硫氨酸,0.05g/L苯丙氨酸,0.05g/L脯氨酸,0.05g/L丝氨酸,0.05g/L酪氨酸,0.05g/L缬氨酸,20g/L琼脂(平板)。
实施例2:重组酵母菌的诱导表达。
挑取重组工程菌的单菌落到SC-U培养基中,30℃振荡培养过夜。然后按2%接种量接种到碳源为葡萄糖(终浓度为20g/L)的新鲜培养基上,培养8h,此部分为生物量的积累。然后再无菌环境中,集菌弃上清,洗菌并将菌体转移到碳源为半乳糖(终浓度为20g/L)的新鲜的筛选培养基中诱导。诱导时间为48h。菌液于6000rpm,4℃离心10min,弃上清。
其中,碳源为葡萄糖的培养基配方为:6.7g/L YNB,20g/L葡萄糖,0.1g/L腺嘌呤,0.1g/L精氨酸,0.1g/L半胱氨酸,0.1g/L亮氨酸,0.1g/L赖氨酸,0.1g/L苏氨酸,0.1g/L色氨酸,0.05g/L天冬氨酸,0.05g/L组氨酸,0.05g/L异亮氨酸,0.05g/L甲硫氨酸,0.05g/L苯丙氨酸,0.05g/L脯氨酸,0.05g/L丝氨酸,0.05g/L酪氨酸,0.05g/L缬氨酸。
其中,碳源为半乳糖的培养基配方为:6.7g/L YNB,20g/L半乳糖,0.1g/L腺嘌呤,0.1g/L精氨酸,0.1g/L半胱氨酸,0.1g/L亮氨酸,0.1g/L赖氨酸,0.1g/L苏氨酸,0.1g/L色氨酸,0.05g/L天冬氨酸,0.05g/L组氨酸,0.05g/L异亮氨酸,0.05g/L甲硫氨酸,0.05g/L苯丙氨酸,0.05g/L脯氨酸,0.05g/L丝氨酸,0.05g/L酪氨酸,0.05g/L缬氨酸。
实施例3:酶活测定方法的确立。
取实施例2中的菌体沉淀,菌体20mg,用磷酸钾缓冲液(pH7.0)洗涤两次,洗涤后的沉淀置液氮中研磨破碎,并用磷酸钾缓冲液(pH7.0)洗出,破碎后的菌液于12000rpm,4℃离心15min。取上清即为粗酶液。精密称取样品,配制成1.4ml体系,其中stevioside的终浓度为1g/L、UDP-葡萄糖为1g/L,并加入2g/L Mgcl2;10mg/L BSA混匀,最后加入400μl粗酶液并加入磷酸钾缓冲液(pH7.0)至体系为1.4ml,起始反应。30℃保温12h后,高温煮沸终止反应。离心,取上清作为样品。HPLC方法检测反应体系中rebaudiosideA甙含量。实验结果表明,rebaudioside A的产量最高可到达到750mg/L,说明该重组工程菌能够表达产酶并且该酶能够催化stevioside生成rebaudioside A。
HPLC法色谱分析条件如下:
色谱柱:Lichrospher NH2柱(250mm×4.6mm,5μm);流动相为乙睛∶水(80∶20;V∶V);流速:1mL·min-1;柱温:40℃;检测波长:210nm。
实施例4:建立全细胞催化反应体系。
取实施例2中的沉淀转移至用50ml小三角瓶中,建立全细胞催化反应体系。此反应体系为10ml,其中菌体20mg。底物stevioside 1g/L;20g/L的葡萄糖;MgCl2 4g/L;通透剂普郎尼克F-685g/L;用磷酸钾缓冲液定容至10ml,pH调节为7.0,200rpm,30℃,反应48h后,取样品离心,将上清样品被存在-20℃备于液相分析。通过加入葡萄糖,以此利用酵母代谢途径产生UDPG作为辅底物的方法,使得rebaudioside A的产量可到达到60mg/L。
实施例5:最佳MgCl2浓度。
取实施例2中的菌体沉淀20mg,按照实例4的方法,转移至用50ml小三角瓶中,加入终浓度为20g/L的葡萄糖,底物stevioside 1g/L,Mgcl2,通透剂普郎尼克F-68 5g/L,用磷酸钾缓冲液定容至10ml,pH调至7.0。按上述方法,取六份平行样,加入的MgCl2浓度分别为1g/L、2g/L、4g/L、6g/L、8g/L、10g/L,30℃,200rpm,反应48h后,取样品离心,将上清样品被存在-20℃备于液相分析。其中MgCl2为10g/L时,rebaudioside A产量最低为20mg/L;MgCl2为1g/L时,rebaudioside A的产量为45mg/L;MgCl2为6g/L时,rebaudioside A的产量最高为82mg/L。
实施例5:最佳普郎尼克F-68浓度。
取实施例2中的菌体沉淀20mg,按照实例4的方法,转移至用50ml小三角瓶中,加入终浓度为20g/L的葡萄糖,底物stevioside 1g/L,Mgcl2 6g/L,通透剂普郎尼克F-68,用磷酸钾缓冲液定容至10ml,pH调至7.0。按上述方法,取四份平行样,加入的普郎尼克F-68浓度分别为1g/L、5g/L、10g/L、15g/L,30℃,200rpm,反应48h后,取样品离心,将上清样品被存在-20℃备于液相分析。其中普郎尼克F-68为1g/L时rebaudioside A产量最低为48mg/L;普郎尼克F-68为15g/L时,rebaudioside A的产量为65mg/L;普郎尼克F-68为10g/L时,rebaudioside A的产量最高为90mg/L。
实施例5:加入代谢调节物质UMP。
取实施例2中的菌体沉淀20mg,按照实例4的方法,转移至用50ml小三角瓶中,加入终浓度为20g/L的葡萄糖,底物stevioside 1g/L,MgCl2 6g/L,通透剂普郎尼克F-6810g/L,并加入UMP,用磷酸钾缓冲液定容至10ml,pH调至7.0。取三份平行样,加入的UMP浓度分别为0.5g/L、1.5g/L、3g/L,30℃,200rpm,反应48h后,取样品离心,将上清样品被存在-20℃备于液相分析。其中UMP为0.5g/L时,rebaudioside A产量最低为56mg/L;UMP为3g/L时,rebaudioside A的产量为91mg/L;UMP为1.5g/L时,rebaudioside A的产量最高为115mg/L。
实施例6:加入代谢调节物质丁二酸。
取实施例2中的菌体沉淀20mg,按照实例4的方法,转移至用50ml小三角瓶中,加入终浓度为20g/L的葡萄糖,底物stevioside 1g/L,MgCl2 6g/L,通透剂普郎尼克F-6810g/L,并加入5.4g/L NaOH,丁二酸,用磷酸钾缓冲液定容至10ml,pH调至7.0。取六份平行样,加入的丁二酸浓度分别为5g/L、6g/L、7g/L、8g/L、9g/L、10g/L,30℃,200rpm,反应48h后,取样品离心,将上清样品被存在-20℃备于液相分析。其中丁二酸为5g/L时,rebaudioside A产量最低为105mg/L;丁二酸为10g/L时,rebaudioside A的产量为175mg/L;丁二酸为9g/L时,rebaudioside A的产量最高为180mg/L。
实施例7:加入代谢调节物质乳清酸。
取实施例2中的菌体沉淀20mg,按照实例4的方法,转移至用50ml小三角瓶中,加入终浓度为20g/L的葡萄糖,底物stevioside 1g/L,MgCl2 6g/L,通透剂普郎尼克F-68 10g/L,并加入乳清酸;用磷酸钾缓冲液定容至10ml,pH调至7.0。取五份平行样,加入的乳清酸浓度分别为1g/L、2g/L、3g/L、4g/L、5g/L,30℃,200rpm,反应48h后,取样品离心,将上清样品被存在-20℃备于液相分析。其中乳清酸为5g/L时,rebaudioside A产量最低为80mg/L;乳清酸为1g/L时,rebaudioside A的产量为203mg/L;乳清酸为2g/L时,rebaudioside A的产量最高为270mg/L。
实施例8:加入代谢调节物质柠檬酸。
取实施例2中的菌体沉淀20mg,按照实例4的方法,转移至用50ml小三角瓶中,加入终浓度为20g/L的葡萄糖,底物stevioside 1g/L,MgCl2 6g/L,通透剂普郎尼克F-6810g/L,并加入柠檬酸;用磷酸钾缓冲液定容至10ml,pH调至7.0。取五份平行样,加入的柠檬酸浓度分别为10g/L、12g/L、15g/L、18g/L、20g/L,30℃,200rpm,反应48h后,取样品离心,将上清样品被存在-20℃备于液相分析。其中柠檬酸为10g/L时,rebaudioside A产量最低为454mg/L;柠檬酸为20g/L时,rebaudioside A的产量为625mg/L;柠檬酸为15g/L时,rebaudioside A的产量最高为675mg/L。
实施例9:最佳反应PH。
取实施例2中的菌体沉淀20mg,按照实例4的方法,转移至用50ml小三角瓶中,加入终浓度为20g/L的葡萄糖,底物stevioside 1g/L,MgCl2 6g/L,通透剂普郎尼克F-6810g/L,并加入柠檬酸15g/L,用磷酸钾缓冲液定容至10ml,按上述方法共做五个平行样,其中pH分别调至6.8、7.0、7.2、7.5、7.8。于30℃,200rpm进行催化反应,反应48h后,取样品离心,将上清样品被存在-20℃备于液相分析。其中pH为7.8时,rebaudioside A的产量最低,为306mg/L;pH为6.8时,rebaudioside A的产量为698mg/L;pH为7.2时,rebaudioside A的产量达到最高,为705mg/L。
实施例10:最佳反应温度。
取实施例2中的菌体沉淀20mg,按照实例4的方法,转移至用50ml小三角瓶中,加入终浓度为20g/L的葡萄糖,底物stevioside 1g/L,Mgcl2 6g/L,通透剂普郎尼克F-6810g/L,并加入柠檬酸15g/L;用磷酸钾缓冲液定容至10ml,pH调至7.2。按上述方法取五份平行样分别于不同温度下进行反应,25℃、30℃、37℃、42℃,200rpm,反应48h后,取样品离心,将上清样品被存在-20℃备于液相分析。其中25℃时,rebaudiosideA的产量最低为78mg/L;42℃时,rebaudioside A的产量为750mg/L;37℃时,rebaudiosideA的产量达到最高,为835mg/L。
实施例11:最佳反应时间。
取实施例2中的菌体沉淀20mg,按照实例4的方法,转移至用50ml小三角瓶中,加入终浓度为20g/L的葡萄糖,底物stevioside 1g/L,Mgcl2 6g/L,通透剂普郎尼克F-6810g/L,并加入柠檬酸15g/L;用磷酸钾缓冲液定容至10ml,pH调至7.2。于37℃,200rpm进行催化反应,分别于反应12h、24h、36h、48h、60h、72h、84h、96取样,样品离心,将上清样品被存在-20℃备于液相分析。其中在12h时,rebaudioside A产量最低,为178mg/L;48h时,rebaudioside A的产量为867mg/L;72h时,rebaudioside A的产量达到最高,为875mg/L。
Claims (10)
1.一种产甜叶菊糖基转移酶UGT76G1的基因工程菌,其特征在于它是将UGT76G1编码基因插入PYes2载体的EcoRI和XhoI酶切位点之间,构建了重组质粒,再将重组质粒导入表达宿主酿酒酵母Saccharomyces cerevisiaeYPH499中得到的工程菌;
其中,所述的UGT76G1编码基因为GenBank,No.GenBank:AY345974.1,该基因序列命名为UGT。
2.权利要求1所述的基因工程菌的构建方法,其特征在于,该方法包括如下步骤:
1)用限制性内切酶EcoR I和Sal I双酶切UGT基因片段和PYes2载体,连接UGT基因片段纯化产物与PYes2载体,得到重组质粒PYes2-UGT;
2)将重组质粒PYes2-UGT转化至DH5α感受态细胞,得到重组大肠杆菌DH5α-PYes2-UGT,选取阳性克隆;
3)将鉴定后的阳性克隆的质粒导入酿酒酵母Saccharomyces cerevisiaeYPH499中,得到基因工程菌YPH499-PYes2-UGT。
3.权利要求1所述的基因工程菌的诱导表达方法,其特征在于,以半乳糖为诱导剂诱导基因工程菌产酶。
4.根据权利要求3所述的基因工程菌的诱导表达方法,其特征在于,将基因工程菌按2~5%接种量接种到碳源为20g/L葡萄糖的培养基上,培养8~16h,然后收集菌体,将菌体转移到碳源为20g/L半乳糖的培养基中诱导,诱导时间为48~60h;所述的碳源为20g/L葡萄糖的培养基配方为:6.7g/L YNB,20g/L葡萄糖,0.1g/L腺嘌呤,0.1g/L精氨酸,0.1g/L半胱氨酸,0.1g/L亮氨酸,0.1g/L赖氨酸,0.1g/L苏氨酸,0.1g/L色氨酸,0.05g/L天冬氨酸,0.05g/L组氨酸,0.05g/L异亮氨酸,0.05g/L甲硫氨酸,0.05g/L苯丙氨酸,0.05g/L脯氨酸,0.05g/L丝氨酸,0.05g/L酪氨酸,0.05g/L缬氨酸;所述的碳源为20g/L半乳糖的培养基配方为:6.7g/L YNB,20g/L半乳糖,0.1g/L腺嘌呤,0.1g/L精氨酸,0.1g/L半胱氨酸,0.1g/L亮氨酸,0.1g/L赖氨酸,0.1g/L苏氨酸,0.1g/L色氨酸,0.05g/L天冬氨酸,0.05g/L组氨酸,0.05g/L异亮氨酸,0.05g/L甲硫氨酸,0.05g/L苯丙氨酸,0.05g/L脯氨酸,0.05g/L丝氨酸,0.05g/L酪氨酸,0.05g/L缬氨酸。
5.权利要求1所述的基因工程菌在生产莱鲍迪甙A中的应用。
6.根据权利要求5所述的应用,其特征在于,利用全细胞催化法,将甜菊甙转化为莱鲍迪甙A。
7.根据权利要求6所述的应用,其特征在于,以诱导表达后的基因工程菌为全细胞催化剂,通过加入表面活性剂改变细胞的通透性,以甜菊甙和葡萄糖为底物,添加镁离子以及调节代谢物质,反应得到莱鲍迪甙A。
8.根据权利要求7所述的应用,其特征在于,基因工程菌的用量按湿菌体计为2g/L;葡萄糖的用量为20g/L;甜菊甙的用量为1g/L;所述的表面活性剂为普郎尼克F-68,用量为1~10g/L;镁离子使用MgCl2,用量为1~10g/L。
9.根据权利要求7所述的应用,其特征在于,所述的调节代谢物质为UMP、丁二酸、乳清酸或柠檬酸,UMP用量为0.5~3g/L,丁二酸用量为5~10g/L,乳清酸用量为1~5g/L,柠檬酸用量为10~20g/L。
10.根据权利要求7所述的应用,其特征在于,所述的反应在磷酸钾缓冲液体系中完成,反应pH6.8~7.8,反应温度25~42℃,反应时间12h~96h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100291582A CN102559528B (zh) | 2012-02-09 | 2012-02-09 | 一种产甜叶菊糖基转移酶ugt76g1的基因工程菌及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100291582A CN102559528B (zh) | 2012-02-09 | 2012-02-09 | 一种产甜叶菊糖基转移酶ugt76g1的基因工程菌及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102559528A true CN102559528A (zh) | 2012-07-11 |
CN102559528B CN102559528B (zh) | 2013-08-21 |
Family
ID=46406139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012100291582A Expired - Fee Related CN102559528B (zh) | 2012-02-09 | 2012-02-09 | 一种产甜叶菊糖基转移酶ugt76g1的基因工程菌及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102559528B (zh) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102796789A (zh) * | 2012-08-14 | 2012-11-28 | 成都南诺格生物科技有限责任公司 | 甜菊醇转化为甜菊单苷的方法 |
CN103397064A (zh) * | 2013-08-14 | 2013-11-20 | 苏州汉酶生物技术有限公司 | 一种酶法制备瑞鲍迪甙m的方法 |
CN103952407A (zh) * | 2014-04-10 | 2014-07-30 | 广东希普生物科技股份有限公司 | 一种解除葡萄糖抑制效应的gal1启动子及其应用 |
CN105658081A (zh) * | 2013-07-31 | 2016-06-08 | 帝斯曼知识产权资产管理有限公司 | 甜菊糖苷 |
CN106536536A (zh) * | 2014-05-05 | 2017-03-22 | 科纳根公司 | 无热量甜味剂 |
CN106754595A (zh) * | 2016-12-13 | 2017-05-31 | 南京工业大学 | 一株重组菌及其在催化莱鲍迪甙a生成莱鲍迪甙d中的应用 |
CN104232496B (zh) * | 2014-09-18 | 2017-06-06 | 广州康琳奈生物科技有限公司 | 一种重组毕赤酵母工程菌及其在合成莱鲍迪苷a中的应用 |
CN106834389A (zh) * | 2016-12-13 | 2017-06-13 | 南京工业大学 | 一种重组菌催化莱鲍迪甙a制备莱鲍迪甙m2的方法 |
CN106929525A (zh) * | 2017-03-03 | 2017-07-07 | 南京工业大学 | 一种基因工程菌及其在制备莱鲍迪甙a中的应用 |
CN107548417A (zh) * | 2015-04-14 | 2018-01-05 | 康纳根有限公司 | 使用工程化全细胞催化剂生产无热量甜味剂 |
CN107920548A (zh) * | 2015-08-06 | 2018-04-17 | 嘉吉公司 | 用于产生甜菊醇糖苷的发酵方法 |
CN108396044A (zh) * | 2011-08-08 | 2018-08-14 | 埃沃尔瓦公司 | 甜菊醇糖苷类的重组生产 |
CN108486160A (zh) * | 2018-03-13 | 2018-09-04 | 兴化格林生物制品有限公司 | 高密度发酵合成莱鲍迪苷a的方法 |
CN108949802A (zh) * | 2018-06-25 | 2018-12-07 | 浙江皇冠科技有限公司 | 一种高产CpG ISS工程菌构建方法与用途 |
CN109234340A (zh) * | 2018-09-29 | 2019-01-18 | 四川盈嘉合生科技有限公司 | 重组酵母菌催化合成莱鲍迪苷m的方法 |
US11168343B2 (en) | 2014-08-11 | 2021-11-09 | Evolva Sa | Production of steviol glycosides in recombinant hosts |
US11274328B2 (en) | 2018-09-29 | 2022-03-15 | Sichuan Ingia Biosynthetic Co., Ltd. | Methods for producing rebaudioside D and rebaudioside M and compositions thereof |
CN114703159A (zh) * | 2022-03-15 | 2022-07-05 | 华南理工大学 | 一种葡糖基转移酶突变体及其应用 |
US11396669B2 (en) | 2016-11-07 | 2022-07-26 | Evolva Sa | Production of steviol glycosides in recombinant hosts |
US11466302B2 (en) | 2014-09-09 | 2022-10-11 | Evolva Sa | Production of steviol glycosides in recombinant hosts |
-
2012
- 2012-02-09 CN CN2012100291582A patent/CN102559528B/zh not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
INVITROGEN: "《pYES2 Cat. No.V825-20》", 《INVITROGEN USER MANUAL》 * |
LEILA LAOUAR ET AL.: "YEAST PERMEABILIZATION WITH SURFACANTS", 《BIOTECHNOLOGY LETTERS》 * |
RICHMAN ET AL.: "AY345974.1", 《GENEBANK》 * |
TANIA V. HUMPHREY ET AL.: "Spatial organisation of four enzymes from Stevai rebaudiana that are involved in steviol glycoside sythesis", 《PLANT MOLECULAR BIOLOGY》 * |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108396044A (zh) * | 2011-08-08 | 2018-08-14 | 埃沃尔瓦公司 | 甜菊醇糖苷类的重组生产 |
CN102796789A (zh) * | 2012-08-14 | 2012-11-28 | 成都南诺格生物科技有限责任公司 | 甜菊醇转化为甜菊单苷的方法 |
CN105658081A (zh) * | 2013-07-31 | 2016-06-08 | 帝斯曼知识产权资产管理有限公司 | 甜菊糖苷 |
CN103397064A (zh) * | 2013-08-14 | 2013-11-20 | 苏州汉酶生物技术有限公司 | 一种酶法制备瑞鲍迪甙m的方法 |
CN103952407A (zh) * | 2014-04-10 | 2014-07-30 | 广东希普生物科技股份有限公司 | 一种解除葡萄糖抑制效应的gal1启动子及其应用 |
CN106536536A (zh) * | 2014-05-05 | 2017-03-22 | 科纳根公司 | 无热量甜味剂 |
US10654881B2 (en) | 2014-05-05 | 2020-05-19 | Conagen Inc. | Non-caloric sweetener |
US10450339B2 (en) | 2014-05-05 | 2019-10-22 | Conagen Inc. | Non-caloric sweetener |
US10597418B2 (en) | 2014-05-05 | 2020-03-24 | Conagen Inc. | Non-caloric sweetener |
US10941174B2 (en) | 2014-05-05 | 2021-03-09 | Conagen Inc. | Non-caloric sweetener |
US11168343B2 (en) | 2014-08-11 | 2021-11-09 | Evolva Sa | Production of steviol glycosides in recombinant hosts |
US11466302B2 (en) | 2014-09-09 | 2022-10-11 | Evolva Sa | Production of steviol glycosides in recombinant hosts |
CN104232496B (zh) * | 2014-09-18 | 2017-06-06 | 广州康琳奈生物科技有限公司 | 一种重组毕赤酵母工程菌及其在合成莱鲍迪苷a中的应用 |
CN107548417B (zh) * | 2015-04-14 | 2021-11-09 | 康纳根有限公司 | 使用工程化全细胞催化剂生产无热量甜味剂 |
CN107548417A (zh) * | 2015-04-14 | 2018-01-05 | 康纳根有限公司 | 使用工程化全细胞催化剂生产无热量甜味剂 |
US10752928B2 (en) | 2015-04-14 | 2020-08-25 | Conagen Inc. | Production of non-caloric sweeteners using engineered whole-cell catalysts |
CN107920548A (zh) * | 2015-08-06 | 2018-04-17 | 嘉吉公司 | 用于产生甜菊醇糖苷的发酵方法 |
US11396669B2 (en) | 2016-11-07 | 2022-07-26 | Evolva Sa | Production of steviol glycosides in recombinant hosts |
CN106754595B (zh) * | 2016-12-13 | 2019-10-22 | 南京工业大学 | 一株重组菌及其在催化莱鲍迪甙a生成莱鲍迪甙d中的应用 |
CN106834389B (zh) * | 2016-12-13 | 2020-03-17 | 南京工业大学 | 一种重组菌催化莱鲍迪甙a制备莱鲍迪甙m2的方法 |
CN106754595A (zh) * | 2016-12-13 | 2017-05-31 | 南京工业大学 | 一株重组菌及其在催化莱鲍迪甙a生成莱鲍迪甙d中的应用 |
CN106834389A (zh) * | 2016-12-13 | 2017-06-13 | 南京工业大学 | 一种重组菌催化莱鲍迪甙a制备莱鲍迪甙m2的方法 |
CN106929525A (zh) * | 2017-03-03 | 2017-07-07 | 南京工业大学 | 一种基因工程菌及其在制备莱鲍迪甙a中的应用 |
CN106929525B (zh) * | 2017-03-03 | 2020-07-03 | 南京工业大学 | 一种基因工程菌及其在制备莱鲍迪甙a中的应用 |
CN108486160A (zh) * | 2018-03-13 | 2018-09-04 | 兴化格林生物制品有限公司 | 高密度发酵合成莱鲍迪苷a的方法 |
CN108949802A (zh) * | 2018-06-25 | 2018-12-07 | 浙江皇冠科技有限公司 | 一种高产CpG ISS工程菌构建方法与用途 |
WO2020062436A1 (zh) * | 2018-09-29 | 2020-04-02 | 四川盈嘉合生科技有限公司 | 重组酵母菌催化合成莱鲍迪苷m的方法 |
US11274328B2 (en) | 2018-09-29 | 2022-03-15 | Sichuan Ingia Biosynthetic Co., Ltd. | Methods for producing rebaudioside D and rebaudioside M and compositions thereof |
CN109234340A (zh) * | 2018-09-29 | 2019-01-18 | 四川盈嘉合生科技有限公司 | 重组酵母菌催化合成莱鲍迪苷m的方法 |
CN109234340B (zh) * | 2018-09-29 | 2020-06-09 | 四川盈嘉合生科技有限公司 | 重组酵母菌催化合成莱鲍迪苷m的方法 |
CN114703159A (zh) * | 2022-03-15 | 2022-07-05 | 华南理工大学 | 一种葡糖基转移酶突变体及其应用 |
CN114703159B (zh) * | 2022-03-15 | 2023-05-26 | 林影 | 一种葡糖基转移酶突变体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102559528B (zh) | 2013-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102559528B (zh) | 一种产甜叶菊糖基转移酶ugt76g1的基因工程菌及其应用 | |
US11725223B2 (en) | Microorganisms for diterpene production | |
US11060124B2 (en) | Methods for making high intensity sweeteners | |
US10273519B2 (en) | Diterpene production in Yarrowia | |
EP1354944B1 (en) | Ginsenoside glycosidase which hydrolyzes ginsenoside glycosyl and the use thereof | |
KR102540615B1 (ko) | 스테비올 글리코시드의 생합성 제조 및 이를 위한 방법 | |
CN106754595B (zh) | 一株重组菌及其在催化莱鲍迪甙a生成莱鲍迪甙d中的应用 | |
JP2021513867A (ja) | モグロシドを含むトリテルペノイドの微生物生産 | |
BR112017004712B1 (pt) | Hospedeiro recombinante que produz um precursor de glicosídeo de esteviol, métodos para produzir um precursor de glicosídeo de esteviol, um esteviol ou um ou mais glicosídeos de esteviol, cultura do dito hospedeiro e lisado da cultura do dito hospedeiro | |
CN112867799A (zh) | 通过全细胞生物转化产生甜菊醇糖苷 | |
EP3862426A2 (en) | Udp-glycosyltransferases | |
CN101691389B (zh) | 一种提高甜菊糖甜质的方法 | |
CN109750071A (zh) | 一种生物催化合成莱鲍迪苷m的方法 | |
JP2022530706A (ja) | ウリジン二リン酸依存性グリコシルトランスフェラーゼ酵素 | |
CN107922913B (zh) | 甜菊醇糖苷转运 | |
US20210040491A1 (en) | Kaurenoic acid hydroxylases | |
CN109154012B (zh) | 使用aobgl11同源体的甜菊醇及甜菊醇糖苷的制造方法 | |
KR101340079B1 (ko) | 테라박터 속 유래 β―글루코시다제를 이용한 PPT 타입 진세노사이드의 생물전환 | |
CN110892068B (zh) | Udp-糖基转移酶 | |
US10548828B2 (en) | Use of 3,6-anhydro-L-galactose for preventing dental caries | |
JP2019532655A (ja) | ゲラニルゲラニルピロリン酸シンターゼ | |
WO2008062555A1 (fr) | Nouveau polypeptide ayant une activité épimérase et son utilisation | |
BR112019011525A2 (pt) | ácido caurenoico hidroxilases | |
CN106929525A (zh) | 一种基因工程菌及其在制备莱鲍迪甙a中的应用 | |
CN113930377A (zh) | 一株全细胞催化提高莱鲍迪苷a含量的工程菌 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130821 Termination date: 20140209 |